A new triplet for chronic lymphocytic leukaemia: zanubrutinib–venetoclax–obinutuzumab

Abstract

In this issue of The Lancet Haematology, Jacob D Soumerai and colleagues1 report the results of a multicentre, single-arm, phase 2, trial testing the activity and safety of the zanubrutinib, venetoclax, and obinutuzumab combination in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma. The primary endpoint of the trial was the proportion of patients that reached unmeasurable minimal residual disease (uMRD) in both the peripheral blood and bone marrow assessed by ten-colour flow cytometry at the local site and using a less than 10–4 cutoff.